PCSK9 and atherosclerosis: Treatment and regression of atherosclerosis to improve CAD is based on conventional therapy including statins, bile acid sequestrants and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (to reduce circulating LDL cholesterol), beta blockers, Ca2+ channel blockers or diuretics (to attenuate intravascular sheer stress and intracellular Ca2+ burden), and platelet aggregation inhibitors (to prevent intracoronary thrombotic events) [62].